Kornimate/medical-research-clean huggingface dataset:
brain connectivity analysis

Conditions: Neural Injury

Summary: stroke remains the leading cause of permanent disability. the neuromodulation technique of transcranial direct current stimulation (tdcs) has the potential to serve as an adjuvant therapy to enhance neuronal connectivity following stroke. by combining electroencephalography (eeg) and tdcs, this study aims to investigate changes in network connectivity and cerebral plasticity, which are key factors in functional recovery after stroke. the objectives are to: 1) analyze how tdcs modulates neuronal activity, 2) evaluate persistent effects in follow-up assessments, and 3) predict patient outcomes. studies on human subjects will be complemented by research in a mouse model of stroke to: 1) identify the molecular mechanisms underlying tdcs effects on functional recovery, 2) establish correlations among functional, molecular, and connectivity indices, and 3) assess the efficacy of biomimetic nanoparticles in targeting injured brain tissue to reduce inflammation, enhance neuronal plasticity, and support functional recovery.


Eligibility criteria:
inclusion criteria: age 18-90 * first ischemic stroke occurring 3-30 days after onset * residual upper limb function * ability to provide informed consent and understand instructions exclusion criteria: * severe spasticity (ashworth \>2) * presence of additional neurological diseases * significant comorbidities * history of intracerebral hemorrhage * severe neglect * contraindications to tdcs

Keywords: non invasive brain stimulation inflammation
cannabidiol effects on fear extinction in social phobia

Conditions: Social Anxiety Disorder

Summary: the investigators will randomly assign participants with social anxiety disorder to receive oral cannabidiol (cbd) or placebo. participants will undergo a fear conditioning and extinction trial, and the investigators will examine whether cbd increases the degree of fear reduction during extinction.

this will be a double-blind, randomized controlled trial of cannabidiol (cbd) vs. placebo for potentiating fear extinction in adult outpatients with social anxiety disorder (sad). after providing written informed consent and passing medical screening, participants will be assessed for sad and other mental health concerns. they will then engage in a fear conditioning paradigm in which an electrical stimulation is applied to the wrist that is aversive but not painful (at a level determined by each participant) paired with pictures of angry faces. following the fear conditioning paradigm, they will receive orally administered cbd or placebo. they will then undergo a fear extinction phase in which the conditioned angry faces are shown repeatedly with no further electrical stimulus. fear toward the conditioned faces following extinction will be measured using galvanic skin response (gsr) and a visual analog scale of self-reported fear. the investigators predict that cbd, compared to placebo, will result in lower gsr and self-reported fear ratings.

Eligibility criteria:
inclusion criteria: 1. age 18 and above 2. any gender 3. any race/ethnicity 4. primary diagnosis of sad according to the diamond 5. at least moderate severity of sad as evidenced by a diamond severity rating of 4 (moderate) or higher 6. able to speak, read and write english (this is necessary because the study measures are only validated in english) 7. concurrent medications will be allowed so long as there is not a substantial risk of interaction with cbd 8. able/willing to consent to participate in study exclusion criteria: 1. \<18 years old 2. active substance use disorder or mania according to the diamond 3. severe risk of suicide or non-suicidal self-injury in the interviewer's judgment 4. current or past schizophrenia spectrum disorder according to the diamond 5. developmental disability, including autism spectrum disorder, according to clinical interview 6. history of organic brain illness or head injury with loss of consciousness \> 5 minutes 7. liver function abnormalities as detected by liver functioning test 8. history of allergic reaction to cbd according to clinical interview 9. unable or unwilling to abstain from cbd or tetrahydrocannabinol use for 24 hr prior to study participation 10. pregnancy or lack of adequate contraception 11. any clinical factors that would preclude the participant from providing informed consent or otherwise participating in the research, according to the interviewer's judgment

Keywords: cannabidiol, fear extinction
study on the mechanism of immune inflammation in cognitive impairment of depression

Conditions: Depression

Summary: the patients with depression were observed and followed up to evaluate the changes of symptoms and cognitive function in patients with depression at different time points before and after drug treatment. at the same time, immunometabolism indicators in serum, urine and stool were detected to screen out immunoinflammatory markers related to cognitive function and treatment response in patients with depression, hoping to provide a new strategy for optimal treatment of depression.

1. participants were included according to the inclusion and exclusion criteria, and demographic data of depressed patients and healthy controls were recorded, including age, sex, ethnicity, occupation, etc. subjects in the depression group were treated with antidepressants (as recommended by the guidelines) and were followed up baseline, 2 weeks, 8 weeks, 12 weeks, and 24 weeks after treatment, respectively. at each follow-up point, symptoms were assessed using hamilton depression scale (hamd), hamilton anxiety scale (hama), depression screening scale (phq-9) and generalized anxiety scale (gad-7), and cognitive function was assessed using thinc-it at three follow-up points: baseline, 12 weeks after treatment, and 24 weeks after treatment. general data were compared between patients with depression and healthy controls at baseline. 2. the depression group was followed up. serum and fecal of patients with depression were collected at 5 follow-up points at baseline, 2 weeks, 8 weeks, 12weeks and 24 weeks after treatment, and serum metabolic indexes and fecal metagenome were detected.

Eligibility criteria:
inclusion criteria: * age 18-60 years old, male or female; * meet the diagnostic criteria for depression in the international classification of diseases-10 (icd-10), and the hamilton depression scale (hamd) score ≥18 points; * junior high school education and above, can cooperate with the completion of relevant scales and sample collection; * did not receive antidepressant therapy at admission or took medication for less than 14 days; and the duration of drug withdrawal ≥3 months; * no history of infection and taking hormones, antibiotics or anti-inflammatory drugs in the past 1 month; * history of physical diseases such as centerless, liver, kidney and gastrointestinal tract, active infection, active or chronic inflammation, autoimmune diseases, etc. exclusion criteria: * pregnant and lactating women; * clinically significant or unstable medical conditions, including congestive heart failure, liver and kidney failure, cancer, immune and metabolic endocrine diseases; * patients with acute or chronic infection, taking anti-inflammatory drugs, cortisol hormones, and receiving antibiotics for 3 consecutive days in the past 1 month; * patients with neuropsychiatric diseases other than depression.

Keywords: depression immune metabolism cognitive function
influence of intrathecal dexamethasone administration for proximal femoral fractures

Conditions: Femoral Fracture; Cognition Disorders; Cortisol; Hypersecretion

Summary: spinal anesthesia blocks acute pain in older patients with femur fracture. delirium is a common complication seen after femur fracture, affecting approximately 10-16% of patients. it is associated with increased mortality at 1st year, delayed rehabilitation efforts, prolonged length of hospital stay, poorer functional outcomes, and increased risk of nursing home placement. intrathecal dexamethasone administration improves quality of anesthesia in patients with femur fracture compared to conventional spinal anesthesia.

the aim of this research was to establish the influence of intrathecal dexamethasone administration in spinal anaesthesia with levobupivacaine on postoperative pain and changes of consciousness, values of cortisol levels and quality of treatment for patients with femoral fractures compared to spinal anaesthesia with only local anaesthetic. the study was planned as a prospective, observational, randomised clinical trial. a total of 60 patients asa2 and asa3 status, scheduled for surgical procedures were sorted into two groups and underwent surgery in spinal anesthesia with levobupivacaine with or without dexamethsone.

Eligibility criteria:
inclusion criteria: * cooperative asa 2 and asa 3 status patients with proximal femoral fractures of one leg * agreed to be enrolled in the study (informed consent signed) exclusion criteria: * patients refused to be enrolled in the study * patients with pre-existing cognitive disturbances before surgery * conditions or diseases with corticosteroid therapy, long term corticosteroid, diabetes mellitus, neurological conditions or tumors, neuroendocrine disorders or tumors * breaking the study protocols * patients who no longer wanted to be enrolled in the study * unexpected events when the study already started

Keywords: spinal anesthesia femoral fracture dexamethasone
calcium dobesilate versus coasting for prevention of ovarian hyperstimulation syndrome

Conditions: Infertility

Summary: the purpose of this study is to compare the effect of oral calcium dobesilate versus costing in the prevention of ovarian hyperstimulation syndrome (ohss) in high-risk women underwent intracytoplasmic sperm injection (icsi).

two hundred and twenty women at risk of ovarian hyperstimulation syndrome during icsi cycles will be randomly scheduled into two equal groups. in group a, (calcium dobesilate group), 1 cap / 8 hs doxium ( 500mg) will be given at day of hcg injection and for 3 weeks ; while in group b (coasting group), coasting (withholding gonadotrophins while maintaining pituitary suppression) follow up every day by measuring e2 for 3 days then either giving triggering or cycle cancellation is done

Eligibility criteria:
inclusion criteria: * infertile women undergoing intracytoplasmic sperm injection or polycystic ovarian syndrome (pco) with one of the following: * presence of more than 20 follicles by ultrasound * e2 more than 3000 pg/ml * retrieval of more than 15 follicles exclusion criteria: * none
anti-inflammatory effects of rivaroxaban versus dabigatran

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared with dabigatran in patients with atrial fibrillation.

previous study showed that administration of rivaroxaban reduced expression of proinflammatory mediators in apolipoprotein e-deficient mice. however, it is unknown whether the anti-inflammatory markers are decreased in patients with atrial fibrillation receiving novel oral anticoagulants.

Eligibility criteria:
inclusion criteria: * non-valvular atrial fibrillation * a chads2-vasc score of 1 or more exclusion criteria: * contraindication for rivaroxaban or dabigatran * stroke or systemic embolism, acute coronary syndromes or peripheral artery disease within 6 months before enrollment * acute heart failure * severe chronic renal failure (creatinine clearance \< 30ml/min.) * receiving dual antiplatelet therapy * patients with a body weight of 50kg or less * uncontrolled hypertension * active malignancy, collagen disease, or infectious disease * patients undergoing surgery within 6 months before enrollment * patients who are planned to undergoing catheter ablation for atrial fibrillation * patients who are not allowed to participate in the trial by judgement of the treating physician

Keywords: atrial fibrillation anticoagulation inflammation
measuring retinal vessel caliber in relation to dark adaptation and blood glucose level

Conditions: Diabetes Mellitus

Summary: the overall objective is to investigate, whether retinal blood vessel diameter change during the energy consuming dark adaptation process and if responses vary between low and high blood glucose.

all subjects are being studied using the same procedure. the study schedule takes place from 8 a.m. to 12 a.m. every time. each subject shows up on one single day. subjects are to show up fasting overnight with a break in insulin and/or oral antidiabetic treatment. the study eye of each subject will be selected by randomisation. we seek to have an equal distribution of right and left eyes overall. a first set of images will be taken after 5 minutes in "standardised daylight", in a room without light from outside, which eliminates any concerns about weather variations. after this the room is completely darkened. 2 set of images will be taken in the dark adapted state after 20 and 40 minutes. subsequently the patient ingests the ogtt and will reach maximum blood glucose level after about 60-90 minutes. at this time, the subjects undergo the same "photo session" as above with high blood glucose levels.

Eligibility criteria:
inclusion criteria: * type 2 diabetic individuals. * minimal or no diabetic retinopathy defined by no more than five microaneurysms or dot hemorrhages per eye on three non-stereoscopic 50 degree color fundus photographs exclusion criteria: * test individuals with significant cataract, prior surgery to the eye, diabetic retinopathy, other serious eye disease, hypertension, other serious systemic disease

Keywords: diabetes mellitus retinal vessels physiology
micro- and macrovascular adaptations in patients with peripheral arterial disease during supervised exercise therapy

Conditions: PAOD (Peripheral Arterial Obstructive Disease)

Summary: given that previous studies demonstrated the feasibility of the required mri techniques, we propose to study the macro- and microvascular adaptations in paod patients undergoing supervised exercise therapy. it is expected to provide valuable insights into the contribution of each vascular mechanism to the rehabilitation and to identify which vascular mechanism fails or is insufficient for a successful rehabilitation. improvement of future treatment requires the identification of relevant adaptive mechanisms. with this we will provide early noninvasive mri readout tools to diagnose and monitor the potential rehabilitation during any form of therapy for paod that affects the peripheral vasculature.


Eligibility criteria:
inclusion criteria: * intermittent claudication according to a positive rose-edingburgh questionnaire * rest ankle-brachial pressure index (abpi) \< 0,90 or 10% decline in abpi after exercise * arterial stenosis/occlusion of femoro-popliteal territory according to duplex/mra measurements * able to ondergo exercise therapy exclusion criteria: * chronic or acute critical ischemia * treated by or planned for vascular surgery or percutaneous transluminal angioplasty * recent onset \<2 months * unable to perform treadmill exercise * diabetes mellitus * contra-indications for (gadolinium-enhanced) mri or thigh cuff inflation
interchromosomal insertion carriers pgt-sr

Conditions: Interchromosomal Breakpoint; Infertility

Summary: interchromosomal insertions (it) are rare and complex structural rearrangements. theoretically, the risk to have a child to term with a malformation or mental retardation can reach 50% related to the proportion of unbalanced gametes produced from behavior of chromosomes during meiosis. however, the meiotic segregation of it has rarely been studied. this study provide an accurate reproductive risk of it carriers resulting from a combined analysis of sperm-fish and preimplantation genetic testing for structural rearrangement (pgt-sr) management of it carriers.


Eligibility criteria:
inclusion criteria: - adult patient whom carrying insertional translocation in the context of pgt-sr management exclusion criteria: - patient who reject the study protocol

Keywords: patients carriers of insertional translocation (it) several years of miscarriages abrotions and primary infertility interchromosomal insertion pgt-sr sperm.
the long-term safety and efficacy of serpinpc in subjects with hemophilia who completed a sponsored serpinpc clinical trial

Conditions: Hemophilia a; Hemophilia B; Hemophilia a with Inhibitor; Hemophilia B with Inhibitor

Summary: the purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (pk) profile of prophylactic serpinpc in participants with hemophilia


Eligibility criteria:
inclusion criteria: * male participants greater than or equal to (\>=) 12 and less than or equal to (\<=) 65 years of age at the time of informed consent * completed participation in a sponsored serpinpc hemophilia clinical trial and, in the opinion of the investigator, was compliant with the study including compliance with diary entries. * capable of providing written informed consent (adolescent assent and parent/guardian consent when appropriate) for participation exclusion criteria: * previous deep vein thrombosis and pulmonary embolism, myocardial infarction, or embolic stroke * participation in another interventional clinical trial, except for serpinpc trials * any other significant conditions or comorbidities that, in the opinion of the investigator, would make the subject unsuitable for enrolment or could interfere with participation in or completion of the study * treatment with anticoagulant or antiplatelet drugs

Keywords: hemophilia serpinpc
"cognitive, motor and sleep evaluation in patients with ischemic stroke of basal ganglia after thrombectomy"

Conditions: Post-stroke Disorders

Summary: the goal of this interventional study is to learn about the clinical outcomes of acute ischemic stroke treated with mechanical thrombectomy resulting in a selective ischemia of the basal ganglia. the main question it aims to answer is: • defining the prevalence and clinical features of possible cognitive, motor and sleep disfuncions occuring after acute ischemic stroke treated with thrombectomy participants will be tested for cognitive, movement and sleep disorders in the acute phase and successively in the long term follow-up.


Eligibility criteria:
inclusion criteria: * participant's age ≥ 18 years * acute ischemic stroke due to occlusion of proximal middle cerebral artery successfully treated with mechanical thrombectomy (mtici ≥ 2b) * signature of specific written informed consent exclusion criteria: * unstable clinical conditions * personal history of cognitive decline before the acute ischemic stroke
use of spect-ct for comparison of dosimetry methods in psma-targeted radioligand therapy (spectacular study)

Conditions: Metastatic Castration-resistant Prostate Cancer

Summary: the spectacular study will enroll patients who are already undergoing a fda approved psma-targeted radioligand treatment cycle. during each treatment cycle, patients will receive 5 additional spect/ct scans to investigate the limits of agreement between dosimetry (absorbed radiation dose) approximation methods and dosimetry using the triexponential fitting method.

all patients with psma-positive tumor and/or metastases of prostate cancer (psma-tmpc) who would be undergoing a psma-targeted radioligand therapy (prlt) based on independent eligibility criteria for the same, will receive 6 serial spect-ct scans for every treatment cycle as a part of our study. the purpose of this investigation is to assess the limits of agreement of commonly employed dosimetry methods used to determine or approximate absorbed doses for organs and tumors compared to a dosimetry method using a triexponential fit requiring 6 post-injection spect-ct scans for all treatment cycles.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male, 18 years old or older 4. histologically or pathologically confirmed prostate adenocarcinoma without predominant small cell component. 5. patient is receiving psma-targeted radioligand therapy (prlt) for treatment of psma-positive tumor and/or metastases of prostate cancer. therapy may be fda approved or investigational in nature under an approved clinical trial. 6. ability to lay flat on scanner for duration of spect-ct imaging studies (1-2 hours) exclusion criteria: 1. assessment by the investigator as unable or unwilling to comply with the requirements of the protocol. 2. eastern cooperative oncology group (ecog) performance status (ps) ≥ 2 3. all criteria which may preclude a psma-radioligand therapy using lu-177 psma-617 or lu-177 psma i\&t to be performed as per standardized guidelines and protocols laid down for these treatments and per decision by the treating physician.
diagnostic sensitivity and specificity of istatis hbsag test at the point-of-care site settings

Conditions: Hepatitis B; Hepatitis B Infection

Summary: a prospective cross-sectional study in which surgically non-invasive sample-taking is done only for the purpose of testing the samples on istatis hbsag test at the point of care.

participants are prospctively recruited and enrolled to participate in the study. the capillary (fingerstick) whole blood, and venous whole blood samples (in serum separating tube (sst) and ethylenediaminetetraacetic acid (edta) tube) are collected by a healthcare professional. serum and plasma samples will be extracted through laboratory processing of the collected serum separating tube and ethylenediaminetetraacetic acid vwb, respectively. the collected samples of capillary will be tested on istatis hbsag test. the collected ethylenediaminetetraacetic acid and serum separating tube vwb will be shipped to the central laboratory to appropriately process and extract serum and plasma samples. ethylenediaminetetraacetic acid vwb, plasma and serum will be tested on istatis hbsag test in the laboratory. an aliquot of the obtained plasma sample will be further tested for reference and confirmatory testing. the results from istatis hbsag test results will not be used for participant management decisions.

Eligibility criteria:
inclusion criteria: * participants/subjects (males, females, and pregnant women) getting tested for hepatitis b virus for one or more of the following reasons: * at risk for hepatitis b virus * having signs and symptoms indicative for hepatitis b virus * routine testing unknown or other reasons will be captured * participants/subjects of 18 years or older and, who are able to give/sign the informed consent. exclusion criteria: * participant younger than 18 years old * participants unable to provide written informed consent

Keywords: hepatitis b rapid test hepatitis b infection hepatitis b istatis test hepatitis b point of care test